Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston reaches enrolment target in TAXUS IV trial:

This article was originally published in Clinica

Executive Summary

Boston Scientific is making progress with its bid to market its paclitaxel-eluting stent in the US, after completing an important enrolment phase of a pivotal trial designed to support regulatory filings for the product. Some 1,172 patients have been enrolled in the TAXUS IV trial - the target number for the study. The patients have received stents of 16mm and 24mm in length and their progress is now being followed. Additional patients requiring 32mm stents are also being enrolled in the study to satisfy a portion of the trial's clinical protocol.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts